News

Key Federal Partners Gather to Plan, Act on Emerging CBRN Threats
October 12, 2021 — Efforts to prepare the U.S. military for a series of evolving threats to both the Warfighter and the nation at-large took center stage during the 2021 CBRN Defense Conference and Exhibition in Baltimore, Maryland from August 16-18... MORE

JPM CBRN Medical Provides Relief and Recovery in the Age of a Global Pandemic
October 4, 2021 — The JPM CBRN Medical team is dedicated to mission, warfighter, and Nation. Their work has been instrumental in bringing novel testing capability to the U.S., delivering critical at-home technology necessary to combat the global COVID-19 pandemic. In spearheading the mission of supporting the warfighter, the team indirectly boosted the local economy and remain ready for the next threat, whether intentional or naturally-occurring... MORE

JPM CBRN Medical Provides Relief and Recovery in the Age of a Global Pandemic
September 8, 2021 — What do global pandemic relief efforts, the U.S. Army, and a local Maryland economy have in common? The answer is fearless innovation, the right people in the right place at the right time, and an Australian-based biotech and diagnostic solutions company named Ellume. ... MORE

DOD Awards $64.6 Million Contract to SiO2 Medical Products to Increase Domestic Production Capacity of Pharmaceutical Vials
July 29, 2021 — IMMEDIATE RELEASE - On July 26, 2021, the Department of Defense (DOD), on behalf of and in coordination with the Department of Health and Human Services (HHS), awarded a $64.6 million contract modification to SiO2 Medical Products to increase domestic production of pharmaceutical vials made of hybrid, glass-equivalent materials... MORE

Biden Administration announces U.S. government procurement of Merck’s investigational antiviral medicine for COVID-19 treatment
June 9, 2021 — The Biden Administration today announced that the U.S. government will procure approximately 1.7 million courses of an investigational antiviral treatment, molnupiravir (MK-4482), for COVID-19 from Merck, pending emergency use authorization (EUA) or approval from the U.S. Food and Drug Administration (FDA).Molnupiravir (MK-4482) is designed to... MORE

Memorandum of Understanding for Acquisition Support Signed Between the Department of Defense and the Department of Health and Human Services
May 26, 2021 — On May 20, 2021, Deputy Secretary of Defense Kathleen Hicks and Deputy Secretary of Health and Human Services (HHS) Andrea Palm signed a memorandum of understanding (MOU) to continue the agencies’ partnership in defeating COVID-19 and preparing for future public health emergencies.The MOU establishes the framework under which the Department of... MORE

Interview with Dr. Kevin Wingerd Chief Technology Officer at the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)
May 25, 2021 — Excerpt from NCT Magazine's Interview with Dr. Kevin Wingerd, Chief Technology Officer at the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)... MORE

The COVID-19 Pandemic: Acquisition of Diagnostic Equipment and Testing Assays for COVID-19 Lays the Groundwork for Vaccine and Treatment Success
May 25, 2021 — In early 2020, the world as we knew it began to change. Lockdowns, mask mandates, and travel bans became the new normal as the world fought to slow the spread of the coronavirus (COVID-19).Priorities began to shift, and the development of safe and efficacious vaccines and therapeutics for COVID-19, along with the diagnostic capability needed to... MORE

DOD & HHS Announce DPA Title III Agreement With Retractable Technologies, Inc. to Expand Domestic Production Capacity for Low Dead-Space Safety Syringes and Needles
May 24, 2021 — As part of the national response to COVID-19, the Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), signed an agreement with Retractable Technologies, Inc. (RTI) to expand the production of the low dead-space (LDS) safety syringes and needles. Government funding allocated was $27.3 million.LDS... MORE

Sanofi-GSK report positive interim results for their COVID-19 shot
May 17, 2021 — An experimental COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the French drugmaker said on Monday... MORE

News Search

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.

JPEO-CBRND Public Affairs Office

The JPEO-CBRND Communications Affairs Network coordinates and responds to all Public Affairs needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.

News Archive - Search by Year and Month

JPEO-CBRND Press Kit

JPEO-CBRND Public Affairs Office